Search Results - "T. Sakakida"

Safety and efficacy of PD-1/PD-L1 blockade in patients with preexisting antinuclear antibodies by Sakakida, T., Ishikawa, T., Chihara, Y., Harita, S., Uchino, J., Tabuchi, Y., Komori, S., Asai, J., Narukawa, T., Arai, A., Tsunezuka, H., Kosuga, T., Konishi, H., Moriguchi, M., Yasuda, H., Hongo, F., Inoue, M., Hirano, S., Ukimura, O., Itoh, Y., Taguchi, T., Takayama, K.

“…Purpose Immune checkpoint inhibitors (ICIs) show promising clinical activity in advanced cancers. However, the safety and efficacy of PD-1/PD-L1 blockade in…”
Get full text

PRABITAS study design: a pragmatic, randomized phase III trial of bi-weekly versus conventional trifluridine/tipiracil plus bevacizumab for metastatic colorectal cancer by T. Sakakida, T. Masuishi, M. Asayama, S. Mitani, A. Makiyama, T. Shimura, H. Takeda, Y. Suwa, Y. Takano, K. Sawada, T. Yomoda, H. Mushiake, Y. Okumura, M. Yokota, M. Yamamoto, Y. Kito, K. Ogawa, H. Matsuoka, M. Ando, M. Tajika, K. Muro, C. Kudo, A. Mishima, K. Murotani, H. Taniguchi

“…Trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) is the established therapy for refractory metastatic colorectal cancer, but there are concerns…”
Get full text